Grant Thornton advises hVIVO Plc on the acquisition of CRS Clinical Research Services Berlin GmbH
Frankfurt, 1. October 2026
On 27 August 2026, hVIVO Plc, London, announced the acquisition of CRS Clinical Research Services Berlin GmbH, Berlin. CRS Berlin is a specialist Phase I/II unit conducting early-phase clinical trials for the pharmaceutical and biotechnology industries.
A Grant Thornton Germany tax team, led by Axel Wagner (Partner), supported hVIVO Plc in connection with the transaction by conducting tax due diligence. Furthermore, Grant Thornton advised hVIVO Plc on the tax-related protection mechanisms to be incorporated into the purchase agreement based on the findings of the tax due diligence.
hVIVO Plc is an international full-service clinical development partner and a world leader in human challenge trials. Listed on AIM, a market of the London Stock Exchange, the company supports pharmaceutical and biotech companies across the entire clinical development process. The group has been present in Germany since the acquisition of CRS Mannheim and CRS Kiel in January 2025; the acquisition of CRS Berlin marks a further step in building its own international clinical network.
CRS Clinical Research Services Berlin GmbH operates a Phase I/II unit in Berlin and is a centre of excellence for trials in dermatology and women's health. CRS Berlin has long-standing relationships with leading pharmaceutical customers and a proven track record with more than 350 studies completed to date.
